The family of anthraquinone-fused
enediyne antitumor antibiotics
was established by the discovery of dynemicin A and deoxy-dynemicin
A. It was then expanded, first by the isolation of uncialamycin,
and then by the addition to the family of tiancimycins A–F
and yangpumicin A. This family of natural products provides
opportunities in total synthesis, biology, and medicine due to their
novel and challenging molecular structures, intriguing biological
properties and mechanism of action, and potential in targeted cancer
therapies. Herein, the total syntheses of tiancimycins A and
B, yangpumicin A, and a number of related anthraquinone-fused
enediynes are described. Biological evaluation of the synthesized
compounds revealed extremely potent cytotoxicities against a number
of cell lines, thus enriching the structure–activity relationships
within this class of compounds. The findings of these studies may
facilitate future investigations directed toward antibody–drug
conjugates for targeted cancer therapies and provide inspiration for
further advances in total synthesis and chemical biology.